Lumos Pharma to Participate in Upcoming Investor Conferences
16 mai 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
10 mai 2022 16h01 HE
|
Lumos Pharma, Inc.
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12...
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
05 mai 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric...
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
26 avr. 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results...
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
11 avr. 2022 08h30 HE
|
Lumos Pharma, Inc.
- Interim Data Anticipated by End of 2022 - - Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, Texas, April 11, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma,...
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
23 mars 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew,...
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
10 mars 2022 16h01 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results...
Lumos Pharma to Participate in Upcoming Investor Conferences
10 mars 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
23 févr. 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
05 janv. 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...